UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The transition from higher education into work: tales of cohesion and fragmentation

Education & training (London), 2007-09, Vol.49 (7), p.516-585

2007

Volltextzugriff (PDF)

Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis

Journal of cystic fibrosis, 2015-11, Vol.14 (6), p.720-726

2015

Volltextzugriff (PDF)

Employee Relations in the Public Sector: Themes and Issues

Employee relations, 2001-02, Vol.23 (1), p.94-104

2001

Volltextzugriff (PDF)

THEORA HAMBLETT PAINTINGS

Illumina ARTbibliographies Modern - unstructured, 1975

1975

Volltextzugriff (PDF)

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

Bioconjugate chemistry, 2005-09, Vol.16 (5), p.1282-1290

2005

Volltextzugriff (PDF)

Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications

American journal of respiratory and critical care medicine, 2020-05, Vol.201 (10), p.1193-1208

2020

Volltextzugriff (PDF)

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Clinical cancer research, 2004-10, Vol.10 (20), p.7063-7070

2004

Volltextzugriff (PDF)

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

American journal of respiratory and critical care medicine, 2014-07, Vol.190 (2), p.175-184

2014

Volltextzugriff (PDF)

Residual Weighted Learning for Estimating Individualized Treatment Rules

Journal of the American Statistical Association, 2017-01, Vol.112 (517), p.169-187

2017

Volltextzugriff (PDF)

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm

Cancer research (Chicago, Ill.), 2015-12, Vol.75 (24), p.5329-5340

2015

Volltextzugriff (PDF)

University Students as Change Agents for Health and Sustainability: A Pilot Study on the Effects of a Teaching Kitchen-Based Planetary Health Diet Curriculum

Nutrients, 2024-02, Vol.16 (4), p.521

2024

Volltextzugriff (PDF)

Heterogeneity and Disparities in the Use of Exception Scores in Pediatric Liver Allocation

American journal of transplantation, 2015-02, Vol.15 (2), p.436-444

2015

Volltextzugriff (PDF)

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Molecular cancer therapeutics, 2015-07, Vol.14 (7), p.1614-1624

2015

Volltextzugriff (PDF)

Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years

The Journal of pediatrics, 2015-11, Vol.167 (5), p.1081-1088.e1

2015

Volltextzugriff (PDF)

Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis

Trends in molecular medicine, 2020-12, Vol.26 (12), p.1068-1077

2020

Volltextzugriff (PDF)

LasR Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum-Sensing Hierarchy in Pseudomonas aeruginosa

mBio, 2016-10, Vol.7 (5)

2016

Volltextzugriff (PDF)

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

The lancet respiratory medicine, 2017-02, Vol.5 (2), p.107-118

2017

Volltextzugriff (PDF)

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa

Journal of cystic fibrosis, 2018-07, Vol.17 (4), p.484-491

2018

Volltextzugriff (PDF)

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis

Thorax, 2016-05, Vol.71 (5), p.454-461

2016

Volltextzugriff (PDF)

Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher

Journal of cystic fibrosis, 2017-05, Vol.16 (3), p.318-326

2017

Volltextzugriff (PDF)

Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary Exacerbations

Chest, 2013-11, Vol.144 (5), p.1659-1670

2013

Volltextzugriff (PDF)

Median age of survival in the 80s! Is there sufficient evidence to believe it?

Journal of cystic fibrosis, 2023-07, Vol.22 (4), p.592-593

2023

Volltextzugriff (PDF)

Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application

American journal of epidemiology, 2024-06

2024

Volltextzugriff (PDF)

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor

Clinical infectious diseases, 2015-03, Vol.60 (5), p.703-712

2015

Volltextzugriff (PDF)

Important steps in the journey to highly effective CFTR modulator access for people with CF

Journal of cystic fibrosis, 2019-09, Vol.18 (5), p.577-578

2019

Volltextzugriff (PDF)

1 – 25 von 495

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(310)
Mit Volltextzugriff
(431)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(494)
Japanisch
(22)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The transition from higher education into work: tales of cohesion and fragmentation

Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis

Employee Relations in the Public Sector: Themes and Issues

THEORA HAMBLETT PAINTINGS

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

Residual Weighted Learning for Estimating Individualized Treatment Rules

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm

University Students as Change Agents for Health and Sustainability: A Pilot Study on the Effects of a Teaching Kitchen-Based Planetary Health Diet Curriculum

Heterogeneity and Disparities in the Use of Exception Scores in Pediatric Liver Allocation

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years

Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis

LasR Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum-Sensing Hierarchy in Pseudomonas aeruginosa

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis

Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher

Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary Exacerbations

Median age of survival in the 80s! Is there sufficient evidence to believe it?

Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor

Important steps in the journey to highly effective CFTR modulator access for people with CF

Suchergebnisse filtern